Additionally, the 36-month beta value for MLYS is -0.31. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MLYS is 38.02M and currently, short sellers hold a 16.02% ratio of that float. The average trading volume of MLYS on May 02, 2025 was 1.14M shares.
MLYS) stock’s latest price update
Mineralys Therapeutics Inc (NASDAQ: MLYS)’s stock price has gone rise by 5.28 in comparison to its previous close of 14.21, however, the company has experienced a 6.17% increase in its stock price over the last five trading days. 247wallst.com reported 2025-05-01 that Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season.
MLYS’s Market Performance
Mineralys Therapeutics Inc (MLYS) has seen a 6.17% rise in stock performance for the week, with a 8.09% gain in the past month and a 45.67% surge in the past quarter. The volatility ratio for the week is 7.14%, and the volatility levels for the past 30 days are at 8.93% for MLYS. The simple moving average for the last 20 days is 12.10% for MLYS’s stock, with a simple moving average of 21.31% for the last 200 days.
Analysts’ Opinion of MLYS
Many brokerage firms have already submitted their reports for MLYS stocks, with H.C. Wainwright repeating the rating for MLYS by listing it as a “Buy.” The predicted price for MLYS in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on July 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see MLYS reach a price target of $30. The rating they have provided for MLYS stocks is “Buy” according to the report published on April 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to MLYS, setting the target price at $27 in the report published on March 07th of the previous year.
MLYS Trading at 14.14% from the 50-Day Moving Average
After a stumble in the market that brought MLYS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.61% of loss for the given period.
Volatility was left at 8.93%, however, over the last 30 days, the volatility rate increased by 7.14%, as shares surge +6.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.52% upper at present.
During the last 5 trading sessions, MLYS rose by +6.17%, which changed the moving average for the period of 200-days by +2.61% in comparison to the 20-day moving average, which settled at $13.35. In addition, Mineralys Therapeutics Inc saw 21.53% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MLYS starting from Slingsby Brian Taylor, who purchase 259,259 shares at the price of $13.50 back on Mar 13 ’25. After this action, Slingsby Brian Taylor now owns 8,903,838 shares of Mineralys Therapeutics Inc, valued at $3,499,996 using the latest closing price.
Rodman David Malcom, the Chief Medical Officer of Mineralys Therapeutics Inc, sale 11,366 shares at $14.53 during a trade that took place back on Apr 14 ’25, which means that Rodman David Malcom is holding 111,686 shares at $165,185 based on the most recent closing price.
Stock Fundamentals for MLYS
The total capital return value is set at -1.01. Equity return is now at value -82.24, with -77.72 for asset returns.
Currently, EBITDA for the company is -177.77 million with net debt to EBITDA at 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.02.
Conclusion
In conclusion, Mineralys Therapeutics Inc (MLYS) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
